ADMA Biologics (ADMA) Stock Statistics & Valuation Metrics

ADMA Biologics has a market cap or net worth of $1.91B. The enterprise value is $1.98B.

ADMA Biologics has 231,772,720 shares outstanding. The number of shares has decreased by -2.65% in one year.

ADMA Biologics’s return on equity (ROE) is 0.31 and return on invested capital (ROIC) is 27.57%.

The current PE Ratio of ADMA Biologics is 11.7. ADMA Biologics’s PEG ratio is -1.09.

In the last 12 months, ADMA Biologics had revenue of 510.17M and earned 146.93M in profits. Earnings per share was 0.62.

In the last 12 months, operating cash flow was 128.32M and capital expenditures -20.42M, giving a free cash flow of 107.90M billion.

ADMA Biologics pays an annual dividend of ―, resulting in a dividend yield of ―

ADMA Biologics upcoming earnings date is Aug 12, 2026, TBA (Confirmed).

ADMA Biologics as a current ratio of 6.71, with Debt / Equity ratio of 52.37%

In the past 12 months, ADMA Biologics has paid 35.73M in taxes.

ADMA Biologics EV to EBITDA ratio is 21.93, with an EV/FCF ratio of 155.96.

ADMA Biologics has $138.15M in cash and marketable securities with $204.41M in debt, giving a net cash position of -$66.25M billion.

Gross margin is 61.27%, with operating margin of 37.53%, and net profit margin of 28.80%.

The average price target for ADMA Biologics is $23.67, which is 11.43% higher than the current price. The consensus rating is Moderate Buy